NEXT-GENERATION OSA NEUROMODULATION
Mask-Free OSA Therapy,
Governed by Physiology
Synergy MedTech is developing a next-generation implantable neuromodulation platform for obstructive sleep apnea—designed to respond to changing physiological needs throughout the night and provide individualized airway support without a mask or tubing.
Synergy’s technology is under development, is not approved by the U.S. Food and Drug Administration, and is not available for commercial use.
OBSTRUCTIVE SLEEP APNEA
At Night, Breathing Is Disrupted. By Day, the Effects Continue.
Obstructive sleep apnea (OSA) occurs when the upper airway repeatedly narrows or collapses during sleep. These recurring events can interrupt airflow, fragment restorative sleep, and affect daily function and long-term health.
Disrupted Sleep
Repeated upper-airway collapse can reduce or stop airflow, often leading to snoring, gasping, drops in blood oxygen, and brief arousals from sleep.
Daytime Function Affected
Fragmented sleep may contribute to fatigue, daytime sleepiness, difficulty concentrating, slower reaction time, and problems with memory and decision-making.
Long-Term Health Risks
Untreated OSA is associated with higher risks of hypertension and cardiovascular conditions, including atrial fibrillation, heart failure, heart attack, and stroke.
About 40 million
U.S. adults are estimated to have moderate-to-severe OSA.
THE UNMET NEED
CPAP Is Effective—But Long-Term Use Can Be Difficult.
CPAP is an effective treatment for obstructive sleep apnea, but its benefits depend on consistent use. For some patients, the mask and tubing, pressurized airflow, nightly setup, and ongoing equipment care can create a substantial treatment burden. Discomfort, leaks, and disrupted sleep may contribute to partial-night use or discontinuation—leaving portions of sleep without therapy.
Nearly 50%
of new CPAP users in a French nationwide cohort had terminated therapy within three years.*
WHAT PATIENTS NEED
A Mask-Free Experience
No external mask or tubing during sleep.
Lower Nightly Treatment Burden
A treatment experience designed to fit more naturally into the patient’s night.
Support designed around physiological needs that can change throughout sleep.
The unmet need is not simply another treatment option,
but a therapy designed to be easier to sustain night after night.
*Pépin J-L, et al. J Clin Med. 2021;10(5):936. French nationwide analysis of 480,000 new CPAP users; therapy termination was defined as cessation of CPAP reimbursements.
A PHYSIOLOGY-GOVERNED APPROACH
The Need for Airway Support
Can Change Throughout the Night.
Sleep is dynamic. As sleep stage, body position, and physiological state change, the support a patient needs may also vary. Synergy is developing a platform intended to align therapy with those changing needs while remaining within clinician-defined parameters.
OUR PLATFORM
A Mask-Free Neuromodulation Platform Designed Around Changing Physiology
Synergy MedTech is developing an implantable neuromodulation platform for obstructive sleep apnea. The platform is intended to align airway support with changing physiological needs throughout the night, operate within clinician-defined treatment parameters, and support personalization over time.
Mask-Free
Designed to provide therapy without an external mask or tubing during sleep.
Physiology-Governed
Intended to align airway support with changing physiological needs across the night.
Clinician-Guided
Designed to operate within treatment parameters established by the clinician.
Personalized Over Time
Designed to support clinician-guided personalization as patient needs evolve over time.
Designed around the patient’s changing physiology—throughout the night and over time.
DESIGN OBJECTIVES
Patient-Centered by Design
LOWER NIGHTLY TREATMENT BURDEN
Designed without an external mask or tubing during sleep.
SUPPORT ACROSS CHANGING NEEDS
Intended to align airway support with physiological needs that may change throughout the night.
MINIMUM NECESSARY STIMULATION
Intended to avoid unnecessary stimulation and limit intervention to the level physiologically needed.
LOWER ADJUSTMENT BURDEN
Clinician-guided tools intended to support patient-specific therapy refinement and reduce repeated manual adjustments over time.
These statements describe product-development objectives, not established clinical outcomes. Synergy’s technology is under development; safety, effectiveness, and clinical benefits have not been established.
DEVELOPMENT
Functional Prototype Development Is Underway
Synergy MedTech is advancing development of a functional integrated prototype for its implantable OSA neuromodulation platform, with U.S.-based build planning and execution underway. Development is guided by identified patient needs, published evidence, and direct clinical input. A foundational U.S. patent application has been filed. The company is preparing for preclinical feasibility evaluation and planning future FDA engagement and IDE-enabling development toward clinical evaluation, subject to regulatory feedback and authorization.
Clinical Foundation
Development is guided by identified patient needs, published evidence, and direct clinical input.
Prototype Development
Functional integrated prototype development and U.S.-based build activities are underway.
Intellectual Property
A foundational U.S. patent application has been filed.
Patent Pending
Regulatory Planning
Future FDA engagement and IDE-enabling development are being planned. Synergy currently anticipates a PMA pathway, subject to FDA feedback.
ABOUT SYNERGY
Building the Next Generation of OSA Neuromodulation
Synergy MedTech is a U.S.-based medical technology company developing a next-generation, mask-free implantable neuromodulation platform for obstructive sleep apnea. Designed around changing physiological needs throughout the night, the platform aims to provide individualized airway support without an external mask or tubing. Our team brings together expertise in respiratory physiology, implantable medical devices, OSA clinical care, product development, commercialization, and company building.
TEAM
Co-Founder & CEO
Louis has more than 20 years of experience in medical technology, with deep expertise in respiratory support developed through work with mechanical ventilation platforms from Dräger and Puritan Bennett. He later co-founded Televia and helped scale it into a leading provider of smart hospital technologies. At Synergy, he leads product strategy and company development and is a named inventor on the company’s foundational U.S. patent filings. He holds an MBA from the University of Chicago Booth School of Business.
Respiratory Support · Product Strategy · Company Building
Co-Founder & CTO
Jim brings more than 20 years of implantable medical-device development experience across neurovascular and cardiovascular applications. He founded Neurovasc Technologies and led the company from product development through strategic acquisition. His work has contributed to more than 15 product families reaching U.S. regulatory authorization and market launch. At Synergy, he leads implantable-system development and translational engineering. He is named on more than 100 U.S. patents and patent applications and has authored more than 30 peer-reviewed publications.
Implantable Neurotechnology · Device Development · Translational Engineering
Chief Medical Advisor
Dr. Kezirian is an internationally recognized specialist in obstructive sleep apnea and sleep surgery. He is a former Chief of Sleep Surgery at UCSF and USC and a Past President of the International Surgical Sleep Society. Board-certified in Otolaryngology and Sleep Medicine, he has led NIH-funded research focused on airway evaluation, patient selection, and clinical outcomes and is an inventor on multiple sleep-technology patents. His education and training include Harvard, Oxford, the University of Pennsylvania, and Stanford.
OSA Clinical Strategy · Patient Selection · Sleep Surgery
CONNECT WITH SYNERGY
Advancing OSA Therapy—Together
Synergy welcomes conversations with clinicians, researchers, strategic partners, investors, and experienced medical-device professionals who share our commitment to advancing a more individualized, mask-free approach to OSA therapy.
Clinical and Research Collaboration
Strategic Partnership
Medical-Device Development
Investor Inquiry
General Corporate Inquiry
Mask-Free for the Patient
Physiology-Governed Throughout the Night
AI-Enabled, Clinician-Guided Personalization Over Time
Designed for the Future of OSA Care